Lupkynis
(Voclosporin)ApprovedSmall molecule
Aurinia PharmaceuticalsVoclosporin is used to treat lupus nephritis, which is kidney damage caused by lupus (an autoimmune disease). It helps reduce inflammation in the kidneys and can improve kidney function in patients with this condition.[2] Lupkynis is currently approved and in use across 9 indications[4].[1]
Lupkynis is one of 175 small molecule programs targeting Lupus Nephritis. It is currently in Approved.
9
Indications
23
Total Trials
4
Active Trials
174
Competitors
4
FDA Applications
NDA/BLA/ANDA regulatory filings
3
Patents
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
105 competitors in Kidney Disease
#DrugCompanyPhaseTrials
1Lupkynis
Aurinia PharmaceuticalsApproved
Myrbetriq
AstellasApproved
Zyloprim
Jazz PharmaceuticalsApproved
Nexavar
BayerApproved
Kisqali
NovartisApproved
Afinitor
NovartisApproved
Medrol
PfizerApproved
Xtandi
AstellasApproved
Lenvima
EisaiApproved
Venclexta
AbbVieApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Lupus Nephritis4 trials
Assessing Residual Inflammation and Macrophage Presence in Lupus Nephritis After 3 Months of Intensified Treatment With Prednisolone, Mycofenolate Mofetil and Voclosporin as Compared to Mycofenolate Mofetil and Prednisolone, an Open Label Randomized Controlled Trial
Recruiting·AAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)·Approved·NCT07760480·55 enrolled
Show 1 more trial
Lupus3 trials
Kidney Transplant2 trials
Psoriasis2 trials
8 more indications
Eye Disease1 trial
Interaction1 trial
Keratoconjunctivitis sicca1 trial
Focal Segmental Glomerulosclerosis1 trial
Treatment1 trial
Examining Distinct Immunophenotypes to Validate and Enhance Rational Treatment in Systemic Lupus
Terminated·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT05306873·12 enrolled
Regulatory
FDA Approval Timeline[5]
Jan 22, 2021
LUPKYNIS
NDA NDA213716
Jan 22, 2021
LUPKYNIS
NDA NDA213716
Apr 29, 2024
LUPKYNIS
NDA NDA213716
Oct 8, 2025
LUPKYNIS
NDA NDA213716
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Lupkynis drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Voclosporin. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]
- [8]